{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:17:13Z","timestamp":1793812633797,"version":"4.6.1"},"reference-count":117,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T00:00:00Z","timestamp":1530748800000},"content-version":"vor","delay-in-days":369,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Metabolism"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.cmet.2017.04.011","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T16:16:31Z","timestamp":1494519391000},"page":"27-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":320,"title":["Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology"],"prefix":"10.1016","volume":"26","author":[{"given":"Ele","family":"Ferrannini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmet.2017.04.011_bib1","doi-asserted-by":"crossref","first-page":"C475","DOI":"10.1152\/ajpcell.00180.2008","article-title":"Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody","volume":"295","author":"Balen","year":"2008","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.cmet.2017.04.011_bib2","doi-asserted-by":"crossref","first-page":"F2","DOI":"10.1152\/ajprenal.00614.2014","article-title":"Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea","volume":"309","author":"Bankir","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.cmet.2017.04.011_bib3","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2337\/diab.31.10.923","article-title":"Insulin resistance in diabetic ketoacidosis","volume":"31","author":"Barrett","year":"1982","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2017.04.011_bib4","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1681\/ASN.2006030216","article-title":"Mechanisms for renal blood flow control early in diabetes as revealed by chronic flow measurement and transfer function analysis","volume":"17","author":"Bell","year":"2006","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.cmet.2017.04.011_bib5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2017.04.011_bib6","first-page":"S124","article-title":"Nephron mass as a risk factor for progression of renal disease","volume":"63","author":"Brenner","year":"1997","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.cmet.2017.04.011_bib7","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2337\/db16-0049","article-title":"Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism","volume":"65","author":"Briand","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2017.04.011_bib8","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/nature07813","article-title":"AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity","volume":"458","author":"Cant\u00f3","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2017.04.011_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1152\/physrev.00042.2012","article-title":"Renal autoregulation in health and disease","volume":"95","author":"Carlstr\u00f6m","year":"2015","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.cmet.2017.04.011_bib10","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1172\/JCI100559","article-title":"The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man","volume":"12","author":"Chasis","year":"1933","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2017.04.011_bib11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cmet.2017.04.011_bib12","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/ki.2014.246","article-title":"Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes","volume":"86","author":"Cherney","year":"2014","journal-title":"Kidney Int."},{"issue":"Suppl 1","key":"10.1016\/j.cmet.2017.04.011_bib13","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1097\/01.hjh.0000467485.28062.c1","article-title":"Contrasting influences of renal function on blood pressure and HbA1c reduction with empagliflozin in patients with type 2 diabetes and hypertension","volume":"33","author":"Cherney","year":"2015","journal-title":"J.\u00a0Hypertens."},{"key":"10.1016\/j.cmet.2017.04.011_bib14","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1007\/s00125-016-4008-2","article-title":"The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes","volume":"59","author":"Cherney","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmet.2017.04.011_bib15","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1210\/endo.138.3.5015","article-title":"Changes in facilitative glucose transporter messenger ribonucleic acid levels in the diabetic rat kidney","volume":"138","author":"Chin","year":"1997","journal-title":"Endocrinology"},{"key":"10.1016\/j.cmet.2017.04.011_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.cmet.2017.04.011_bib17","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/ki.1997.463","article-title":"Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients","volume":"52","author":"Christensen","year":"1997","journal-title":"Kidney Int."},{"key":"10.1016\/j.cmet.2017.04.011_bib18","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1046\/j.1523-1755.1999.00676.x","article-title":"Impaired autoregulation of the glomerular filtration rate in patients with nondiabetic nephropathies","volume":"56","author":"Christensen","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.cmet.2017.04.011_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/00365510151067965","article-title":"The impact of glycaemic control on autoregulation of glomerular filtration rate in patients with non-insulin dependent diabetes","volume":"61","author":"Christensen","year":"2001","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.cmet.2017.04.011_bib20","series-title":"The Kidney","article-title":"Renal metabolism: relation to renal function","author":"Cohen","year":"1986"},{"key":"10.1016\/j.cmet.2017.04.011_bib21","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.2337\/db13-1130","article-title":"Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individuals","volume":"63","author":"Daniele","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2017.04.011_bib22","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/dc15-2688","article-title":"Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes","volume":"39","author":"Daniele","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmet.2017.04.011_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdiacomp.2015.10.013","article-title":"The EMPA-REG study: what has it told us? A diabetologist\u2019s perspective","volume":"30","author":"DeFronzo","year":"2016","journal-title":"J.\u00a0Diabetes Complications"},{"key":"10.1016\/j.cmet.2017.04.011_bib24","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1172\/JCI107996","article-title":"The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man","volume":"55","author":"DeFronzo","year":"1975","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2017.04.011_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1172\/JCI108463","article-title":"The effects of glucose and insulin on renal electrolyte transport","volume":"58","author":"DeFronzo","year":"1976","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2017.04.011_bib26","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/dc13-0387","article-title":"Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes","volume":"36","author":"DeFronzo","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmet.2017.04.011_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.cmet.2017.04.011_bib28","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/oby.2012.59","article-title":"Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats","volume":"20","author":"Devenny","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.cmet.2017.04.011_bib29","doi-asserted-by":"crossref","first-page":"G946","DOI":"10.1152\/ajpgi.00286.2014","article-title":"Selective sodium- dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release","volume":"308","author":"Dobbins","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.cmet.2017.04.011_bib30","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1172\/JCI106150","article-title":"Familial renal glycosuria: a genetic reappraisal of hexose transport by kidney and intestine","volume":"48","author":"Elsas","year":"1969","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2017.04.011_bib31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2214\/ajr.160.1.8416654","article-title":"Kidney dimensions at sonography: correlation with age, sex, and habitus in 665 adult volunteers","volume":"160","author":"Emanian","year":"1993","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.cmet.2017.04.011_bib32","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Seshasai","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2017.04.011_bib33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1172\/JCI102424","article-title":"Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose","volume":"30","author":"Farber","year":"1951","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2017.04.011_bib34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0026-0495(88)90110-2","article-title":"The theoretical bases of indirect calorimetry: a review","volume":"37","author":"Ferrannini","year":"1988","journal-title":"Metabolism"},{"key":"10.1016\/j.cmet.2017.04.011_bib35","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/eurheartj\/ehv239","article-title":"Impact of glucose-lowering drugs on CV disease in type 2 diabetes","volume":"36","author":"Ferrannini","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cmet.2017.04.011_bib36","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects","volume":"8","author":"Ferrannini","year":"2012","journal-title":"Nat. Rev Endocrinol."},{"key":"10.1016\/j.cmet.2017.04.011_bib37","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1172\/JCI111133","article-title":"Effect of fatty acids on glucose production and utilization in man","volume":"72","author":"Ferrannini","year":"1983","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2017.04.011_bib38","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00125-011-2112-x","article-title":"Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study","volume":"54","author":"Ferrannini","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmet.2017.04.011_bib39","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2337\/db12-0707","article-title":"Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance","volume":"62","author":"Ferrannini","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2017.04.011_bib40","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2017.04.011_bib41","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2337\/dc15-0355","article-title":"Energy balance after sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Ferrannini","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmet.2017.04.011_bib42","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2017.04.011_bib43","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmet.2017.04.011_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/dc16-2724","article-title":"Renal handling of ketones in response to sodium-glucose co-transporter-2 inhibition in patients with type 2 diabetes","volume":"40","author":"Ferrannini","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmet.2017.04.011_bib45","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1056\/NEJMsa053935","article-title":"Explaining the decrease in U.S. deaths from coronary disease, 1980-2000","volume":"356","author":"Ford","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2017.04.011_bib46","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.cmet.2017.04.011_bib47","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diab Vasc. Dis. Res."},{"key":"10.1016\/j.cmet.2017.04.011_bib48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","article-title":"Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications","volume":"27","author":"Gerich","year":"2010","journal-title":"Diabet Med."},{"key":"10.1016\/j.cmet.2017.04.011_bib49","doi-asserted-by":"crossref","first-page":"C348","DOI":"10.1152\/ajpcell.00115.2012","article-title":"Regulation of the human Na+-dependent glucose cotransporter hSGLT2","volume":"303","author":"Ghezzi","year":"2012","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.cmet.2017.04.011_bib50","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/cphy.c130008","article-title":"Monocarboxylic acid transport","volume":"3","author":"Halestrap","year":"2013","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.cmet.2017.04.011_bib51","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.clinthera.2016.09.001","article-title":"Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes","volume":"38","author":"Heise","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.cmet.2017.04.011_bib52","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0002-9343(82)90490-9","article-title":"The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies","volume":"72","author":"Hostetter","year":"1982","journal-title":"Am. J. Med."},{"key":"10.1016\/j.cmet.2017.04.011_bib53","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/1479164114559852","article-title":"SGLT-2 inhibitors and CV risk: proposed pathways and review of on-going outcome trials","volume":"12","author":"Inzucchi","year":"2015","journal-title":"Diab Vasc. Dis. Res."},{"key":"10.1016\/j.cmet.2017.04.011_bib54","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.2337\/dc16-2793","article-title":"Incidence of ketoacidosis in the Danish type 2 diabetes population before and after introduction of sodium-glucose cotransporter 2 inhibitors-A nationwide, retrospective cohort study, 1995-2014","volume":"40","author":"Jensen","year":"2017","journal-title":"Diabetes Care Mar."},{"key":"10.1016\/j.cmet.2017.04.011_bib55","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1681\/ASN.V86943","article-title":"Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats","volume":"8","author":"Kamran","year":"1997","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.cmet.2017.04.011_bib56","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diab Obes. Metab."},{"key":"10.1016\/j.cmet.2017.04.011_bib57","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/1479164114563304","article-title":"Development of sotagliflozin, a dual sodium-dependent glucose transporter 1\/2 inhibitor","volume":"12","author":"Lapuerta","year":"2015","journal-title":"Diab Vasc. Dis. Res."},{"key":"10.1016\/j.cmet.2017.04.011_bib58","doi-asserted-by":"crossref","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","article-title":"Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models","volume":"7","author":"Liang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cmet.2017.04.011_bib59","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa1408214","article-title":"Glycemic control and excess mortality in type 1 diabetes","volume":"371","author":"Lind","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2017.04.011_bib60","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.2337\/diab.37.11.1470","article-title":"Metabolic effects of low-dose insulin therapy on glucose metabolism in diabetic ketoacidosis","volume":"37","author":"Luzi","year":"1988","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2017.04.011_bib61","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s001250051172","article-title":"Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus","volume":"42","author":"M\u00e4kimattila","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmet.2017.04.011_bib62","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1113\/jphysiol.2003.046268","article-title":"Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane","volume":"553","author":"Marks","year":"2003","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.cmet.2017.04.011_bib63","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1172\/JCI111658","article-title":"Insulin within islets is a physiologic glucagon release inhibitor","volume":"74","author":"Maruyama","year":"1984","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2017.04.011_bib64","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/ki.2010.509","article-title":"Glucose handling by the kidney","author":"Mather","year":"2011","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.cmet.2017.04.011_bib65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdiacomp.2015.10.012","article-title":"EMPA-REG \u2013 the \u201cdiuretic hypothesis\u201d","volume":"30","author":"McMurray","year":"2016","journal-title":"J.\u00a0Diabetes Complications"},{"key":"10.1016\/j.cmet.2017.04.011_bib66","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1210\/jc.2015-2597","article-title":"Effect of dapagliflozin with and without acipimox on insulin sensitivity and insulin secretion in T2DM males","volume":"101","author":"Merovci","year":"2016","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cmet.2017.04.011_bib67","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrcardio.2015.134","article-title":"Pathophysiology and clinical evaluation of acute heart failure","volume":"13","author":"Mentz","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.cmet.2017.04.011_bib68","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2017.04.011_bib69","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3181\/00379727-84-20634","article-title":"Effect of insulin on maximal rate of tubular uptake of glucose in non-diabetic humans","volume":"84","author":"Miller","year":"1953","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.cmet.2017.04.011_bib70","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/00365517109090668","article-title":"Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects","volume":"28","author":"Mogensen","year":"1971","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.cmet.2017.04.011_bib71","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.2337\/dc15-0642","article-title":"Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside","volume":"38","author":"Mudaliar","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmet.2017.04.011_bib72","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s00125-015-3845-8","article-title":"Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes","volume":"59","author":"Muscelli","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmet.2017.04.011_bib73","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S2213-8587(15)00424-6","article-title":"Understanding EMPA-REG outcome","volume":"3","author":"Muskiet","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.cmet.2017.04.011_bib74","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.cmet.2012.01.024","article-title":"Interplay between lipids and branched-chain amino acids in development of insulin resistance","volume":"15","author":"Newgard","year":"2012","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2017.04.011_bib75","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.bbrc.2015.10.109","article-title":"Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic \u03b2-cells in obese type 2 diabetic db\/db mice","volume":"470","author":"Okauchi","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cmet.2017.04.011_bib76","doi-asserted-by":"crossref","first-page":"e0146114","DOI":"10.1371\/journal.pone.0146114","article-title":"Influence of familial renal glycosuria due to mutations in the SLC5A2 Gene on changes in glucose tolerance over time","volume":"11","author":"Ottosson-Laakso","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cmet.2017.04.011_bib77","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc13-2338","article-title":"Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial","volume":"37","author":"Perkins","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmet.2017.04.011_bib78","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc12-2391","article-title":"Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study","volume":"36","author":"Polidori","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmet.2017.04.011_bib79","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00125-014-3196-x","article-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes","volume":"57","author":"Polidori","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmet.2017.04.011_bib80","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s13300-016-0201-z","article-title":"Canagliflozin: efficacy and safety in combination with metformin alone or with other antihyperglycemic agents in type 2 diabetes","volume":"7","author":"Qiu","year":"2016","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.cmet.2017.04.011_bib81","first-page":"E1","article-title":"Effect of insulin on uric acid excretion in humans","volume":"268","author":"Qui\u00f1ones Galvan","year":"1995","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.cmet.2017.04.011_bib82","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2017.04.011_bib83","doi-asserted-by":"crossref","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","article-title":"Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia","volume":"306","author":"Rieg","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.cmet.2017.04.011_bib84","first-page":"6775","article-title":"Mechanism of lowered renal threshold for glucose in diabetes","volume":"265","author":"Robertson","year":"1953","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2017.04.011_bib85","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmet.2017.04.011_bib86","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats","volume":"79","author":"Rossetti","year":"1987","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2017.04.011_bib87","doi-asserted-by":"crossref","first-page":"F913","DOI":"10.1152\/ajprenal.00270.2005","article-title":"Rat renal glucose transporter SGLT1 exhibits zonal distribution and androgen-dependent gender differences","volume":"290","author":"Sabolic","year":"2006","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.cmet.2017.04.011_bib88","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1113\/JP271904","article-title":"Revisiting the physiological roles of SGLTs and GLUTs using positron emission tomography in mice","volume":"594","author":"Sala-Rabanal","year":"2016","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.cmet.2017.04.011_bib89","doi-asserted-by":"crossref","first-page":"e86976","DOI":"10.1172\/jci.insight.86976","article-title":"Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications","volume":"1","author":"Sas","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.cmet.2017.04.011_bib90","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1096\/fasebj.9.8.7768357","article-title":"Insulin. Ketone bodies, and mitochondrial energy transduction","volume":"9","author":"Sato","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.cmet.2017.04.011_bib91","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","article-title":"Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects","volume":"13","author":"Sha","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.cmet.2017.04.011_bib92","doi-asserted-by":"crossref","first-page":"35215","DOI":"10.1038\/srep35215","article-title":"A renal olfactory receptor aids in kidney glucose handling","volume":"6","author":"Shepard","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cmet.2017.04.011_bib93","doi-asserted-by":"crossref","first-page":"e009417","DOI":"10.1136\/bmjopen-2015-009417","article-title":"SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","volume":"6","author":"Shyangdan","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmet.2017.04.011_bib94","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/1440-1681.12036","article-title":"Renal oxygenation and hemodynamics in acute kidney injury and chronic kidney disease","volume":"40","author":"Singh","year":"2013","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.cmet.2017.04.011_bib95","doi-asserted-by":"crossref","DOI":"10.1111\/dom.12970","article-title":"SGLT2 and SGLT1 expression in renal tissue of patients with type 2 diabetes","author":"Solini","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.cmet.2017.04.011_bib96","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 inhibitors may predispose to ketoacidosis","volume":"100","author":"Taylor","year":"2015","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cmet.2017.04.011_bib97","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/CIRCULATIONAHA.109.933275","article-title":"Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival","volume":"122","author":"Testani","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.cmet.2017.04.011_bib98","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","article-title":"Diabetic kidney disease","volume":"1","author":"Thomas","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.cmet.2017.04.011_bib99","doi-asserted-by":"crossref","first-page":"F974","DOI":"10.1152\/ajprenal.00149.2007","article-title":"Insulin\u2019s impact on renal sodium transport and blood pressure in health, obesity, and diabetes","volume":"293","author":"Tiwari","year":"2007","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.cmet.2017.04.011_bib100","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI60016","article-title":"Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover","volume":"122","author":"Unger","year":"2012","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2017.04.011_bib101","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmet.2017.04.011_bib102","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.cmet.2017.04.011_bib103","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.cmet.2017.04.011_bib104","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.molmet.2016.06.012","article-title":"Demonstration of a day-night rhythm in human skeletal muscle oxidative capacity","volume":"5","author":"van Moorsel","year":"2016","journal-title":"Mol. Metab."},{"key":"10.1016\/j.cmet.2017.04.011_bib105","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00232-001-0036-y","article-title":"Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat","volume":"182","author":"Vestri","year":"2001","journal-title":"J.\u00a0Membr. Biol."},{"key":"10.1016\/j.cmet.2017.04.011_bib106","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1530\/acta.0.0500079","article-title":"Maximum tubular reabsorption capacity in diabetes mellitus","volume":"50","author":"Vitelli","year":"1965","journal-title":"Acta Endocrinol."},{"key":"10.1016\/j.cmet.2017.04.011_bib107","article-title":"SGLT2 expression is increased in human diabetic nephropathy: SGLT2 inhibition decreases renal lipid accumulation, inflammation and the development of nephropathy in diabetic mice","author":"Wang","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.cmet.2017.04.011_bib108","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2017.04.011_bib109","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2337\/diacare.14.3.220","article-title":"Central role of sodium in hypertension in diabetic subjects","volume":"14","author":"Weidmann","year":"1991","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmet.2017.04.011_bib110","first-page":"F65","article-title":"Control of renal hemodynamics in hyperglycemia: possible role of tubuloglomerular feedback","volume":"252","author":"Woods","year":"1987","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.cmet.2017.04.011_bib111","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mam.2012.11.002","article-title":"Glucose transport families SLC5 and SLC50","volume":"34","author":"Wright","year":"2013","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.cmet.2017.04.011_bib112","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1152\/physiol.00026.2004","article-title":"Surprising versatility of Na+-glucose cotransporters: SLC5","volume":"19","author":"Wright","year":"2004","journal-title":"Physiology"},{"key":"10.1016\/j.cmet.2017.04.011_bib113","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.cmet.2017.04.011_bib114","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/dom.12848","article-title":"SGLT2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: a randomized, open-label, 3-arm parallel comparative exploratory study","volume":"19","author":"Yabe","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.cmet.2017.04.011_bib115","doi-asserted-by":"crossref","first-page":"C1277","DOI":"10.1152\/ajpcell.00296.2010","article-title":"Functional expression of SGLTs in rat brain","volume":"299","author":"Yu","year":"2010","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.cmet.2017.04.011_bib116","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/clpt.2012.58","article-title":"LX4211, a dual SGLT1\/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial","volume":"92","author":"Zambrowicz","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cmet.2017.04.011_bib117","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, CV outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N.\u00a0Engl. J. Med."}],"container-title":["Cell Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1550413117302164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1550413117302164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T13:45:44Z","timestamp":1659015944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1550413117302164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":117,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1550413117302164"],"URL":"https:\/\/doi.org\/10.1016\/j.cmet.2017.04.011","relation":{},"ISSN":["1550-4131"],"issn-type":[{"value":"1550-4131","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology","name":"articletitle","label":"Article Title"},{"value":"Cell Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmet.2017.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}